Roth Capital Raises Cutera, Inc. (CUTR) Price Target to $39.00
Cutera, Inc. (NASDAQ:CUTR) had its price target upped by Roth Capital from $32.00 to $39.00 in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the medical device company’s stock. Roth Capital’s price objective indicates a potential upside of 46.34% from the stock’s current price.
Several other research firms have also commented on CUTR. Maxim Group reiterated a “buy” rating and issued a $33.00 price target (up from $27.00) on shares of Cutera in a research report on Thursday, July 13th. BidaskClub upgraded shares of Cutera from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 12th. Sidoti restated a “buy” rating and set a $32.00 target price (up previously from $30.00) on shares of Cutera in a research report on Friday, July 7th. Zacks Investment Research lowered shares of Cutera from a “buy” rating to a “hold” rating in a research report on Monday, June 26th. Finally, TheStreet lowered shares of Cutera from a “b-” rating to a “c” rating in a research report on Monday, May 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $33.25.
Cutera (NASDAQ CUTR) opened at 26.65 on Tuesday. Cutera has a one year low of $10.54 and a one year high of $29.25. The firm has a market capitalization of $369.32 million, a PE ratio of 102.11 and a beta of 0.60. The stock’s 50 day moving average price is $25.87 and its 200 day moving average price is $21.85.
COPYRIGHT VIOLATION NOTICE: “Roth Capital Raises Cutera, Inc. (CUTR) Price Target to $39.00” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/08/roth-capital-raises-cutera-inc-cutr-price-target-to-39-00.html.
In other Cutera news, Director David A. Gollnick sold 39,204 shares of the stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $22.31, for a total transaction of $874,641.24. Following the transaction, the director now owns 34,136 shares of the company’s stock, valued at $761,574.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Larry Laber sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $25.88, for a total transaction of $25,880.00. Following the transaction, the executive vice president now directly owns 73,140 shares in the company, valued at approximately $1,892,863.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,563 shares of company stock worth $1,485,360. 3.30% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. American International Group Inc. increased its position in Cutera by 7.0% in the first quarter. American International Group Inc. now owns 7,221 shares of the medical device company’s stock worth $149,000 after buying an additional 475 shares in the last quarter. Metropolitan Life Insurance Co. NY bought a new position in Cutera during the first quarter worth $202,000. Trexquant Investment LP bought a new position in Cutera during the first quarter worth $267,000. Russell Investments Group Ltd. bought a new position in Cutera during the fourth quarter worth $321,000. Finally, Driehaus Capital Management LLC bought a new position in Cutera during the first quarter worth $363,000. 82.87% of the stock is currently owned by institutional investors.
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.